FLGT

#2863
Fulgent Genetics, Inc. - Common Stock
20.0 4 USD
+0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
20.04
20.04
Jahresspanne
13.46
31.04
Tagesänderung
+2.30%
Monatliche Änderung
+13.93%
6 month change
+43.45%
Jahresänderung
-15.19%
Vorheriger Schlusskurs
19.5 9
Open
20.0 4
Tief
20.0 4
Hoch
20.0 4
Volumen
67
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Fulgent Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Fulgent Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Fulgent Genetics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Fulgent Genetics, Inc. annual report, FY2025
10-K

Fulgent Genetics, Inc. current report, Q1 FY2022

Full document

Fulgent Genetics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Fulgent Genetics, Inc. (FLGT) on March 29, 2022, covering events occurring on March 28, 2022. The Company is a Delaware corporation headquartered in Temple City, California, with common stock listed on the Nasdaq Global Market.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and policy adoption rather than financial performance results.

Material Changes

On March 28, 2022, the Board of Directors adopted the Incentive Compensation Recoupment Policy (the "Clawback Policy"). This policy allows the Compensation Committee to recoup incentive compensation from executives in cases of serious misconduct or failure to supervise that results in a material violation of law or company policy causing significant financial or reputational harm.

Guidance, Outlook, and Risks

  • Policy Scope: The Clawback Policy applies to equity awards and cash-based performance awards granted on or after the Effective Date.
  • Limitations: Recoupment cannot be sought following a change in control or for awards granted more than three years prior to the triggering event.
  • Compliance: The Company reserves the right to recoup compensation to the extent required by law or exchange listing requirements, regardless of the Policy's specific terms.
  • Outlook: The filing contains no forward-looking guidance or management commentary regarding future financial performance.

Key Facts for Investor Verification

  • Verify the full text of the Incentive Compensation Recoupment Policy attached as Exhibit 10.1.
  • Confirm the specific definitions of "serious misconduct" and "significant financial or reputational harm" within the adopted policy.
  • Review subsequent filings to determine if any executive compensation has been recouped under this new policy.
  • Note that this filing does not contain updated financial statements or operational metrics.

Nachrichten